Table 1.

Baseline demographics and characteristics of the study participants (M±SD or %)

	Total sample		Baclofen group		Placebo group
	n=30	n=18	n=15	n=9	n=15	n=9
Age (years)	46.3±8.6		47.9±9.9		44.7±7.0
Male gender	70		67		73
Hispanic ethnicity	3		7		0
Racea
American Indian	7		13		0
Asian	3		0		7
Caucasian	43		20		67
African-American	33		40		27
Multiracial or others	13		27		0
Heavy drinking days (HDD)	74.3±26.8		78.0±27.3		70.5±26.7
Cigarettes per day (CPD)	24.7±9.4		24.9±10.2		24.4±8.9
Alcohol dependence scale (ADS) score	14.7±7.9		15.8±8.4		13.5±7.5
Fagerström test for nicotine dependence (FTND) score	7.2±1.8		7.1±1.6		7.3±2.1
Smoking contemplation ladder score	5.3±1.4		5.3±1.8		5.3±1.0
Cue-reactivity experiment substudy
Age (Years)		45.2±9.3		45.0±11.6		45.3±6.9
Male Gender		67		67		67
Hispanic Ethnicity		6		11		0
Race
American Indian		6		11		0
Caucasian		44		22		67
African-American		33		33		33
Multiracial or others		17		33		0
Heavy drinking days (HDD)		73.8±26.8		74.3±30.6		73.2±24.2
Cigarettes per day (CPD)		24.7±8.8		24.6±8.9		24.7±9.2
Alcohol dependence scale (ADS) score		16.6±8.4		17.4±9.3		15.8±7.9
Fagerström test for nicotine dependence (FTND) score		7.2±2.1		7.4±1.8		7.0±2.4
Smoking contemplation ladder score		5.4±1.5		5.3±1.9		5.4±1.1

^aThere were no differences in the baseline demographics and characteristics among groups, except for race (X² (4, N=30)=11.2, p=0.025 and with race dichotomized: X² (1, N=30)=6.7, p=0.01). This difference was not significant in the sample that participated in the cue-reactivity experiment substudy